Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Rentokil
RTO
|
$510M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$205M |
| 3 |
TFI International
TFII
|
$146M |
| 4 |
Ambev
ABEV
|
$133M |
| 5 |
Vanguard S&P 500 ETF
VOO
|
$132M |
Top Sells
| 1 |
Microsoft
MSFT
|
$8.38B |
| 2 |
Apple
AAPL
|
$5.18B |
| 3 |
Mastercard
MA
|
$3.67B |
| 4 |
Alphabet (Google) Class C
GOOG
|
$3.38B |
| 5 |
Amazon
AMZN
|
$3.16B |
Sector Composition
| 1 | Technology | 28.11% |
| 2 | Healthcare | 21.42% |
| 3 | Financials | 11.42% |
| 4 | Industrials | 10.68% |
| 5 | Consumer Discretionary | 10.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
NXP Semiconductors
NXPI
$59.2B
| $466M | 0.33% |
2,950,072
-1,678,686
| -36% | -$265M |
|
77
Humana
HUM
$36.5B
| $454M | 0.32% |
885,743
-984,011
| -53% | -$504M |
|
|
HZNP
78
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $449M | 0.32% |
3,949,519
-8,124,517
| -67% | -$925M |
|
79
Ascendis Pharma
ASND
$11.8B
| $445M | 0.32% |
3,643,955
-4,029,561
| -53% | -$492M |
|
80
Bristol-Myers Squibb
BMY
$96B
| $436M | 0.31% |
6,060,223
-8,740,205
| -59% | -$629M |
|
81
Steris
STE
$24.1B
| $427M | 0.31% |
2,312,632
-2,382,194
| -51% | -$440M |
|
82
Analog Devices
ADI
$124B
| $424M | 0.3% |
2,583,182
-1,104,932
| -30% | -$181M |
|
83
Broadridge
BR
$29.9B
| $422M | 0.3% |
3,149,327
-3,072,199
| -49% | -$412M |
|
84
Monster Beverage
MNST
$60.9B
| $422M | 0.3% |
4,154,541
-3,907,881
| -48% | -$397M |
|
85
Globus Medical
GMED
$8.27B
| $418M | 0.3% |
5,633,954
-8,450,430
| -60% | -$628M |
|
86
Corteva
CTVA
$50.4B
| $412M | 0.29% |
7,000,691
-7,148,119
| -51% | -$420M |
|
87
Dayforce
DAY
$11B
| $405M | 0.29% |
6,309,082
-6,025,224
| -49% | -$387M |
|
88
Lamar Advertising Co
LAMR
$12.9B
| $403M | 0.29% |
4,270,301
-4,010,683
| -48% | -$379M |
|
89
ICU Medical
ICUI
$3.15B
| $403M | 0.29% |
2,557,226
-2,457,692
| -49% | -$387M |
|
90
BioMarin Pharmaceuticals
BMRN
$11.2B
| $402M | 0.29% |
3,888,444
-4,371,004
| -53% | -$452M |
|
91
Vertex Pharmaceuticals
VRTX
$100B
| $400M | 0.29% |
1,385,476
-1,617,594
| -54% | -$467M |
|
92
Fidelity National Information Services
FIS
$36.5B
| $398M | 0.28% |
5,870,491
-9,531,221
| -62% | -$647M |
|
93
Cadence Design Systems
CDNS
$95.5B
| $395M | 0.28% |
2,460,638
-3,549,476
| -59% | -$570M |
|
94
Dollar General
DG
$23.9B
| $390M | 0.28% |
1,585,562
-1,337,562
| -46% | -$329M |
|
|
MMP
95
DELISTED
Magellan Midstream Partners, L.P.
MMP
| $388M | 0.28% |
7,736,550
-7,962,184
| -51% | -$400M |
|
96
Sensata Technologies
ST
$4.74B
| $386M | 0.28% |
9,564,236
-9,777,332
| -51% | -$395M |
|
|
CTLT
97
DELISTED
CATALENT, INC.
CTLT
| $370M | 0.26% |
8,216,242
-5,411,084
| -40% | -$244M |
|
98
argenx
ARGX
$43.6B
| $369M | 0.26% |
974,720
-149,850
| -13% | -$56.8M |
|
99
Aramark
ARMK
$10.3B
| $361M | 0.26% |
8,733,106
-8,625,034
| -50% | -$357M |
|
100
Novartis
NVS
$245B
| $357M | 0.25% |
3,933,293
-2,745,247
| -41% | -$249M |
|